GB0921288D0 - Therapies for preventing or suppressing clostridium difficile infection - Google Patents

Therapies for preventing or suppressing clostridium difficile infection

Info

Publication number
GB0921288D0
GB0921288D0 GBGB0921288.7A GB0921288A GB0921288D0 GB 0921288 D0 GB0921288 D0 GB 0921288D0 GB 0921288 A GB0921288 A GB 0921288A GB 0921288 D0 GB0921288 D0 GB 0921288D0
Authority
GB
United Kingdom
Prior art keywords
therapies
preventing
clostridium difficile
difficile infection
suppressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0921288.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Micropharm Ltd
Public Health England
Original Assignee
Health Protection Agency
Micropharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Protection Agency, Micropharm Ltd filed Critical Health Protection Agency
Priority to GBGB0921288.7A priority Critical patent/GB0921288D0/en
Publication of GB0921288D0 publication Critical patent/GB0921288D0/en
Priority to JP2012541584A priority patent/JP5877161B2/ja
Priority to SG2012039616A priority patent/SG181127A1/en
Priority to PCT/GB2010/052035 priority patent/WO2011067616A1/en
Priority to CA2782639A priority patent/CA2782639C/en
Priority to MYPI2012002466A priority patent/MY158712A/en
Priority to BR112012013496A priority patent/BR112012013496A2/pt
Priority to EP10787170.9A priority patent/EP2506877B1/en
Priority to US13/513,555 priority patent/US8921529B2/en
Priority to CN2010800537789A priority patent/CN102740889A/zh
Priority to AU2010325764A priority patent/AU2010325764B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0921288.7A 2009-12-04 2009-12-04 Therapies for preventing or suppressing clostridium difficile infection Ceased GB0921288D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB0921288.7A GB0921288D0 (en) 2009-12-04 2009-12-04 Therapies for preventing or suppressing clostridium difficile infection
AU2010325764A AU2010325764B2 (en) 2009-12-04 2010-12-06 Therapies for preventing or suppressing Clostridium difficile infection
CA2782639A CA2782639C (en) 2009-12-04 2010-12-06 Therapies for preventing or suppressing clostridium difficile infection
SG2012039616A SG181127A1 (en) 2009-12-04 2010-12-06 Therapies for preventing or suppressing clostridium difficile infection
PCT/GB2010/052035 WO2011067616A1 (en) 2009-12-04 2010-12-06 Therapies for preventing or suppressing clostridium difficile infection
JP2012541584A JP5877161B2 (ja) 2009-12-04 2010-12-06 クロストリジウム・ディフィシル感染を予防または抑制するための治療法
MYPI2012002466A MY158712A (en) 2009-12-04 2010-12-06 Therapies for preventnig or suppressing clostridium difficile infection
BR112012013496A BR112012013496A2 (pt) 2009-12-04 2010-12-06 "composição de anticorpo para a prevenção ou supressão da infecção por clostridium difficile e composição farmacêutica para a aplicação oral".
EP10787170.9A EP2506877B1 (en) 2009-12-04 2010-12-06 Therapies for preventing or suppressing clostridium difficile infection
US13/513,555 US8921529B2 (en) 2009-12-04 2010-12-06 Therapies for preventing or suppressing Clostridium difficile infection
CN2010800537789A CN102740889A (zh) 2009-12-04 2010-12-06 用于预防或抑制艰难梭菌感染的疗法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0921288.7A GB0921288D0 (en) 2009-12-04 2009-12-04 Therapies for preventing or suppressing clostridium difficile infection

Publications (1)

Publication Number Publication Date
GB0921288D0 true GB0921288D0 (en) 2010-01-20

Family

ID=41641956

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0921288.7A Ceased GB0921288D0 (en) 2009-12-04 2009-12-04 Therapies for preventing or suppressing clostridium difficile infection

Country Status (10)

Country Link
US (1) US8921529B2 (https=)
EP (1) EP2506877B1 (https=)
JP (1) JP5877161B2 (https=)
CN (1) CN102740889A (https=)
BR (1) BR112012013496A2 (https=)
CA (1) CA2782639C (https=)
GB (1) GB0921288D0 (https=)
MY (1) MY158712A (https=)
SG (1) SG181127A1 (https=)
WO (1) WO2011067616A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709428B2 (en) 2009-02-20 2014-04-29 Health Protection Agency Antibodies to Clostridium difficile toxins
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
SMT201700124T1 (it) 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
AR086199A1 (es) * 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
US9505847B2 (en) * 2011-08-22 2016-11-29 Cnj Holdings Inc Clostridium difficile antibodies
AU2012349753A1 (en) 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
DE102011121237A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN105142612A (zh) 2013-03-08 2015-12-09 奇普拉股份有限公司 用于直肠给药的药物组合物
EP2970400A1 (en) * 2013-03-15 2016-01-20 Sanofi Pasteur, Inc. Toxoid, compositions and related methods
CA2910200A1 (en) * 2013-04-22 2014-10-30 Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
JP6691477B2 (ja) 2013-06-14 2020-04-28 サノフィ パストゥール インコーポレイテッド クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
EP2957570B1 (en) * 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
ES2672045T3 (es) * 2014-07-25 2018-06-12 Biosynth S.R.L. Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas
EP3121272A1 (en) * 2015-07-24 2017-01-25 Zymetech ehf. Novel fish trypsin isoforms and their use
US20190111001A1 (en) * 2016-03-30 2019-04-18 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
GB201701404D0 (en) * 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
GB202019817D0 (en) * 2020-12-15 2021-01-27 Univ Oxford Innovation Ltd Ligand-binding polypeptides and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608225A (ja) 1983-06-29 1985-01-17 Kowa Co 腸管吸収医薬組成物
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
WO1996007430A1 (en) 1994-09-06 1996-03-14 Galagen, Inc. Therapeutic treatment of clostridium difficile associated diseases
CA2203504A1 (en) * 1994-10-24 1996-05-02 James A. Williams Vaccine and antitoxin for treatment and prevention of c. difficile disease
US6096310A (en) 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2305293A3 (en) 1997-10-20 2013-11-06 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6074689A (en) 1998-03-10 2000-06-13 Immucell Corporation Colonic delivery of protein or peptide compositions
US20020009429A1 (en) 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
GB0205206D0 (en) 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
AU2003299527A1 (en) 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
WO2004003145A2 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
LT2857418T (lt) 2004-02-06 2017-09-25 University Of Massachusetts Antikūnai prieš clostridium difficile toksinus ir jų panaudojimas
CA2565368A1 (en) * 2004-04-29 2005-11-24 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Oral formulations comprising bone morphogenetic proteins for treating metabolic bone diseases
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
US7794721B2 (en) 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
CN101363867B (zh) 2008-05-26 2012-12-19 北京庄笛浩禾生物医学科技有限公司 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法
US8709428B2 (en) 2009-02-20 2014-04-29 Health Protection Agency Antibodies to Clostridium difficile toxins
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection

Also Published As

Publication number Publication date
JP5877161B2 (ja) 2016-03-02
CN102740889A (zh) 2012-10-17
JP2013512889A (ja) 2013-04-18
EP2506877B1 (en) 2021-08-04
US8921529B2 (en) 2014-12-30
SG181127A1 (en) 2012-07-30
CA2782639C (en) 2019-02-26
MY158712A (en) 2016-11-15
EP2506877A1 (en) 2012-10-10
WO2011067616A1 (en) 2011-06-09
AU2010325764A1 (en) 2012-06-07
BR112012013496A2 (pt) 2016-08-16
CA2782639A1 (en) 2011-06-09
US20130004561A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
GB0921288D0 (en) Therapies for preventing or suppressing clostridium difficile infection
HUE073517T2 (hu) Bakterioterápia Clostridium difficile vastagbélgyulladásra
EP2637190A4 (en) RELAY
ZA201400678B (en) Alpha-amylase variants
GB0909143D0 (en) Messaging system
PL2490735T3 (pl) Automatyczny wstrzykiwacz
PL2283904T3 (pl) System części konstrukcyjnych
GB201016742D0 (en) Clostridium difficile antigens
EP2391894A4 (en) SYSTEM IN RELATIVE TIME
IL213990A0 (en) Compositions for decontamination
EP2510083A4 (en) SPORIC COMPOSITION FOR CLOSTRIDIUM DIFFICILE SPORTS
GB0914700D0 (en) Location system
EP2486890A4 (en) SUPPORT FOR AN IMPLANT
PL3413000T3 (pl) Układ osłonowy
HRP20160397T1 (hr) Spojevi za liječenje clostridium difficile povezanih bolesti
GB201013048D0 (en) Messaging control system
EP2496718A4 (en) GENOTYPING
IL220114A0 (en) Syringe flange protector
ZA201106615B (en) Messaging system
GB201013060D0 (en) Compounds for the treatment of clostridium difficile associated disease
PL392437A1 (pl) Układ zaworowy
GB201013058D0 (en) Compounds for the treatment of clostridium difficile associated disease
GB201009090D0 (en) Compounds for the treatment of clostridium difficile associated disease
GB201009108D0 (en) Compounds for the treatment of clostridium difficile associated disease
GB201009085D0 (en) Compounds for the treatment of clostridium difficile associated disease

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)